Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vital Images to use iCAD technology

This article was originally published in The Gray Sheet

Executive Summary

iCAD's Second Look CT computer-aided detection (CAD) will be integrated, pending FDA approval, into the firm's Vitrea 2 medical imaging software for diagnostic evaluation of CT and MR image data to detect polyps that could lead to colon cancer under a non-exclusive agreement. Vital Images inked a July deal with CAD-competitor R2 Technology to incorporate the latter firm's ImageChecker CT system with Vitrea 2 for lung nodules (1"The Gray Sheet" July 19, 2004, p. 22). Vital Images is a distributor for R2...

You may also be interested in...

R2 ImageChecker Approval Launches CAD Lung Market; iCAD Preps To Join

FDA approval of R2 Technology's ImageChecker CT CAD system for lung nodules July 8 provides the firm with a comfortable head-start over competitor iCAD, which expects to launch its own system in 2005

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts